Drug Profile
GM 2296
Latest Information Update: 07 Feb 2001
Price :
$50
*
At a glance
- Originator Glycomed
- Developer Genentech; Glycomed
- Class Anti-inflammatories; Anti-ischaemics
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 07 Feb 2001 Discontinued-Preclinical for Inflammation in USA (Unknown route)
- 24 Sep 1998 Profile reviewed
- 24 Sep 1998 Sankyo is a licensee in Japan for GM 2296